PT1149090E - Nova forma cristalina do sal de potassio de (s)-omeprazole - Google Patents

Nova forma cristalina do sal de potassio de (s)-omeprazole

Info

Publication number
PT1149090E
PT1149090E PT00903058T PT00903058T PT1149090E PT 1149090 E PT1149090 E PT 1149090E PT 00903058 T PT00903058 T PT 00903058T PT 00903058 T PT00903058 T PT 00903058T PT 1149090 E PT1149090 E PT 1149090E
Authority
PT
Portugal
Prior art keywords
crystaline
omeprazole
new
salt form
potassium salt
Prior art date
Application number
PT00903058T
Other languages
English (en)
Portuguese (pt)
Inventor
Maths Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1149090E publication Critical patent/PT1149090E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT00903058T 1999-01-28 2000-01-18 Nova forma cristalina do sal de potassio de (s)-omeprazole PT1149090E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound

Publications (1)

Publication Number Publication Date
PT1149090E true PT1149090E (pt) 2003-07-31

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00903058T PT1149090E (pt) 1999-01-28 2000-01-18 Nova forma cristalina do sal de potassio de (s)-omeprazole

Country Status (40)

Country Link
US (1) US6511996B1 (enExample)
EP (1) EP1149090B1 (enExample)
JP (1) JP2002535401A (enExample)
KR (1) KR100624054B1 (enExample)
CN (1) CN1231477C (enExample)
AR (1) AR022425A1 (enExample)
AT (1) ATE236899T1 (enExample)
AU (1) AU768676B2 (enExample)
BG (1) BG65060B1 (enExample)
BR (1) BR0007647A (enExample)
CA (1) CA2357744C (enExample)
CZ (1) CZ300504B6 (enExample)
DE (1) DE60002042T2 (enExample)
DK (1) DK1149090T3 (enExample)
DZ (1) DZ3001A1 (enExample)
EE (1) EE04240B1 (enExample)
EG (1) EG23980A (enExample)
ES (1) ES2193937T3 (enExample)
HK (1) HK1041259B (enExample)
HU (1) HU226766B1 (enExample)
ID (1) ID30095A (enExample)
IL (1) IL144107A0 (enExample)
IS (1) IS2019B (enExample)
MY (1) MY119095A (enExample)
NO (1) NO319719B1 (enExample)
NZ (1) NZ512804A (enExample)
PL (1) PL197881B1 (enExample)
PT (1) PT1149090E (enExample)
RS (1) RS50200B (enExample)
RU (1) RU2237666C2 (enExample)
SA (1) SA00200895B1 (enExample)
SE (1) SE9900274D0 (enExample)
SI (1) SI1149090T1 (enExample)
SK (1) SK285626B6 (enExample)
TN (1) TNSN00017A1 (enExample)
TR (1) TR200102138T2 (enExample)
TW (1) TWI269795B (enExample)
UA (1) UA71594C2 (enExample)
WO (1) WO2000044744A1 (enExample)
ZA (1) ZA200105526B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
WO2004099181A1 (en) 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
BRPI0512522A (pt) * 2004-06-24 2008-03-11 Astrazeneca Ab processo para a preparação de sal de sódio de esomeprazol, composto, formulação farmacêutica, e, método de tratamento
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
AU2006306906B2 (en) * 2005-10-26 2010-02-04 Hanmi Science Co., Ltd. S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
WO2007148213A2 (en) * 2006-06-21 2007-12-27 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2011071982A2 (en) 2009-12-08 2011-06-16 Codexis, Inc. Synthesis of prazole compounds
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
DK1078628T3 (da) 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
ID30095A (id) 2001-11-01
HUP0105313A2 (hu) 2002-05-29
US6511996B1 (en) 2003-01-28
YU53801A (sh) 2004-07-15
EG23980A (en) 2008-02-27
BG105841A (en) 2002-04-30
HU226766B1 (en) 2009-09-28
KR100624054B1 (ko) 2006-09-18
EP1149090A1 (en) 2001-10-31
CZ300504B6 (cs) 2009-06-03
UA71594C2 (uk) 2004-12-15
TNSN00017A1 (fr) 2005-11-10
HK1041259A1 (en) 2002-07-05
BR0007647A (pt) 2001-10-16
IL144107A0 (en) 2002-05-23
DK1149090T3 (da) 2003-06-30
CA2357744A1 (en) 2000-08-03
SE9900274D0 (sv) 1999-01-28
NZ512804A (en) 2003-07-25
CN1231477C (zh) 2005-12-14
BG65060B1 (bg) 2007-01-31
IS2019B (is) 2005-06-15
ZA200105526B (en) 2002-10-04
AU2469400A (en) 2000-08-18
ES2193937T3 (es) 2003-11-16
CZ20012730A3 (cs) 2002-02-13
TR200102138T2 (tr) 2001-12-21
RS50200B (sr) 2009-07-15
CN1339034A (zh) 2002-03-06
AR022425A1 (es) 2002-09-04
DE60002042T2 (de) 2003-12-18
WO2000044744A1 (en) 2000-08-03
ATE236899T1 (de) 2003-04-15
AU768676B2 (en) 2003-12-18
SK285626B6 (sk) 2007-05-03
EP1149090B1 (en) 2003-04-09
CA2357744C (en) 2009-06-16
EE04240B1 (et) 2004-02-16
DE60002042D1 (de) 2003-05-15
SK10372001A3 (sk) 2002-02-05
JP2002535401A (ja) 2002-10-22
TWI269795B (en) 2007-01-01
NO20013665D0 (no) 2001-07-26
RU2237666C2 (ru) 2004-10-10
IS5989A (is) 2001-07-05
NO319719B1 (no) 2005-09-05
PL197881B1 (pl) 2008-05-30
KR20010101699A (ko) 2001-11-14
MY119095A (en) 2005-03-31
SA00200895B1 (ar) 2006-11-11
DZ3001A1 (fr) 2004-03-27
HUP0105313A3 (en) 2003-01-28
HK1041259B (en) 2003-10-24
NO20013665L (no) 2001-07-26
EE200100395A (et) 2002-10-15
SI1149090T1 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
EE04240B1 (et) (S)-omeprasooli kaaliumisool
PT991641E (pt) Forma cristalina de sal sodico de omeprazol
AU2003257850A8 (en) Antibody specific to central tau-protein
EE05483B1 (et) CTLA-4 vastased inimese monoklonaalsed antikehad
EE05627B1 (et) CTLA-4 vastased inimese monoklonaalsed antikehad
DE69906461D1 (de) Wechselaufbausystem
NO20000490D0 (no) Fleksibel senkambolt
PT1274407E (pt) Utilizacao de agonistas de ppar-gama em doencas induzidas por netrofilos
ID27346A (id) Peralatan pengenal suara
DE60041300D1 (de) Sequentielle Bus-Architektur
ID28966A (id) Metoda pemurnian trietanolamina
GB9807464D0 (en) Purification of human acid µ-glucosidase
ID27522A (id) Fasilitas untuk bermain
IL147891A0 (en) Topical use of anti-muscarnic agents
PL342262A1 (en) Heterocyclic toxins of topoisomerases
DK1082575T3 (da) Vandfri krystaller
EE200000690A (et) Kahejuhtmeline mitmekiiruseline akulaadija
HUP0101830A3 (en) Purification carboxaldehyde
IS6626A (is) Kristallskenndur meðferðarmiðill
GB0201545D0 (en) "Water purification system"
MA26840A1 (fr) Cristaux d'inhibiteur d'echangeur sodium-hydrogene de type 1
DE69902582D1 (de) Uhrarmband
ATE232544T1 (de) Selektive inhibitoren des mmp-12
TW402109U (en) Improved elastic structure of spectacle sides
ITMI980151A1 (it) Protein-disolfuro isomerasi come agenti terapeutici